"Could you give us an update on the licensing agreement with the University of Georgia?", asked Jolly. "Initially, we teamed up with the University of Georgia because they had worldwide renowned expertise in coronavirus protease inhibitors, and this is what our coronavirus treatment is centered around," explained Dr. Slilaty. "The University of Georgia had two technologies which were already patented by them and we agreed that they would license them to us on an exclusive basis. In return, we would offer co-development of their compounds in parallel with our own."

Jolly then asked about the progress of the Company's COVID-19 treatment. "We are now at the stage where we have initiated mice studies on our SBFM-PL4 protease inhibitor," said Dr. Slilaty, adding that the Company will also be including the licensed compounds from the University of Georgia in these studies. Dr. Slilaty then elaborated on the process of the mice studies, as well as what would occur in the event of a successful study. "If that were the case, we would file our results with the FDA and request that the FDA authorizes us to proceed to test our compound on actual COVID-19 patients."

The conversation then turned to the Company's development of Adva-27a. "So, that is our flagship anticancer compound," explained Dr. Slilaty. "It is the only drug we're aware of anywhere in the world that works on multidrug resistant cancer cells," he shared. "We're really excited about this. We have ordered a new batch of Adva-27a, and we're expecting delivery of the new batch any time now," said Dr. Slilaty, adding that the Company intends to use the compound in mice studies.

"What's next for the COVID-19 research plan?", asked Jolly. "At the end of the mice studies, we're going to file the data of the mice studies with the FDA and request a review of our results, as well as authorization to proceed with Phase I clinical trials on actual COVID-19 patient volunteers," explained Dr. Slilaty. "What's interesting with our drug is the fact that it can be taken orally at home. There is no need for a hospital setting, as is the case right now with current treatments."

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.